PROPANC BIOPHARMA, INC. Debt Instrument, Fair Value Disclosure
PROPANC BIOPHARMA, INC. (PPCB) had Debt Instrument, Fair Value Disclosure of $293.97 thousand as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2026-07-17
- 2026-03-31: Debt Instrument, Fair Value Disclosure $293.97K.
- 2025-12-31: Debt Instrument, Fair Value Disclosure $293.97K.
- 2025-09-30: Debt Instrument, Fair Value Disclosure $178.88K.
- 2025-06-30: Debt Instrument, Fair Value Disclosure $468.50K.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2026-03-31 | $293.97K S-1 · filed 2026-07-17 |
| 2025-12-31 | $293.97K S-1 · filed 2026-04-10 |
| 2025-09-30 | $178.88K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $468.50K S-1 · filed 2026-07-17 |
| 2025-03-31 | $437.50K 10-Q · filed 2025-05-15 |
| 2025-03-05 | $437.50K S-1 · filed 2026-07-17 |
| 2025-01-05 | $437.50K S-1 · filed 2026-07-17 |
| 2024-06-30 | $352.56K S-1 · filed 2026-07-17 |
| 2023-03-31 | $369.11K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $195.95K 10-Q · filed 2023-02-10 |
| 2022-09-30 | $195.95K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $28.57K 10-K · filed 2023-09-28 |
| 2021-06-30 | $178.37K 10-K · filed 2022-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |